| アブストラクト | Individual case safety reports (ICSRs) are a cornerstone in drug safety surveillance. The knowledge on using these data specifically for children is limited. We studied characteristics of pediatric ICSRs reported to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Public available ICSRs reported in children (0-18 years) to FAERS were downloaded from the FDA-website for the period Jan 2004-Dec 2011. Characteristics of these ICSRs, including the reported drugs and events, were described and stratified by age-groups. We included 106,122 pediatric ICSRs (55% boys and 58% from United States) with a median of 1 drug [range 1-3] and 1 event [1-2] per ICSR. Mean age was 9.1 years. 90% was submitted through expedited (15-days) (65%) or periodic reporting (25%) and 10% by non-manufacturers. The proportion and type of pediatric ICSRs reported were relatively stable over time. Most commonly reported drug classes by decreasing frequency were 'nervous system drugs' (58%), 'antineoplastics' (32%) and 'anti-infectives' (25%). Most commonly reported system organ classes were 'general' (13%), 'nervous system' (12%) and 'psychiatric' (11%) disorders. Duration of use could be calculated for 19.7% of the reported drugs, of which 14.5% concerned drugs being used long-term (>6 months). Knowledge on the distribution of the drug classes and events within FAERS is a key first step in developing pediatric specific methods for drug safety surveillance. Because of several differences in terms of drugs and events among age-categories, drug safety signal detection analysis in children needs to be stratified by each age group. |
|---|
| 投稿者 | de Bie, Sandra; Ferrajolo, Carmen; Straus, Sabine M J M; Verhamme, Katia M C; Bonhoeffer, Jan; Wong, Ian C K; Sturkenboom, Miriam C J M |
|---|
| 組織名 | Department of Medical Informatics, Erasmus University Medical Center, Rotterdam,;the Netherlands; Medicines Evaluation Board, Utrecht, the Netherlands.;the Netherlands; Experimental Medicine Department, Pharmacology Section, Campania;Regional Center of Pharmacovigilance and Pharmacoepidemiology, Second University;of Naples, Naples, Italy.;the Netherlands.;Brighton Collaboration Foundation, Basel, Switzerland; University Children's;Hospital Basel, University of Basel, Basel, Switzerland.;Centre for Safe Medication Practice and Research, Department of Pharmacology and;Pharmacy, University of Hong Kong, Hong Kong, China.;the Netherlands; Department of Epidemiology, Erasmus University Medical Center,;Rotterdam, the Netherlands. |
|---|
